查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1980181

關節疼痛治療注射藥物市場：全球市場規模、佔有率、成長率、類型/應用、區域趨勢及2026-2034年預測分析

Joint Pain Injections Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 144 Pages | 商品交期: 2-3個工作天內

價格

關節疼痛注射市場的成長要素

2025年全球關節疼痛注射市場規模為63.4億美元，預計2026年將成長至69.7億美元，到2034年將達到156.7億美元，預測期內複合年成長率（CAGR）為10.70%。 2025年，北美市場佔主導地位，市場佔有率達45.52%，這主要得益於該地區骨關節炎的高發病率、先進的醫療基礎設施以及有利的醫保報銷政策。受運動傷害日益增多和人們對關節疾病的認知不斷提高的影響，預計到2032年，美國關節疼痛注射市場規模將達到54.9億美元。

關節疼痛注射廣泛用於治療類風濕性關節炎和乾癬性關節炎等肌肉骨骼疾病患者的疼痛和發炎。皮質類固醇注射是首選治療方法，直接注射到受影響關節。肌肉骨骼疾病盛行率的不斷上升以及主要企業致力於研發新治療方法是推動市場成長的主要因素。

新冠疫情期間，由於就診人數減少，市場成長放緩。然而，隨著人們對肌肉骨骼疾病的認知不斷提高以及創新產品的持續推出，疫情後市場正在復甦。

市場趨勢

市場正逐漸轉向微創療法，例如富血小板血漿（PRP）注射、透明質酸（HA）注射和血漿基質療法。這些治療方法因其藥物吸收迅速、止痛效果持久且不適感輕微，正獲得越來越多的患者支持。

例如，2021年8月，Bioventus投資了Trice Medical公司，以拓展其用於整形外科手術的微創技術。正在進行的研究，例如埃默里大學於2022年開展的利用間質幹細胞（MSCs）和骨髓濃縮液（BMAC）治療膝骨關節炎的3期臨床試驗，都支持創新治療方法的日益普及。

市場成長要素

1. 運動傷害日益增加：韌帶和肌肉損傷的增加推動了關節疼痛注射療法的需求。 2022年，美國國家運動安全委員會報告稱，與運動器材相關的損傷超過44.5萬例，顯示符合疼痛管理治療條件的患者群體正在擴大。

2. 對肌肉骨骼疾病的認知提高：政府主導的各項措施和宣傳宣傳活動促進了關節內注射療法的應用，從而推動了市場擴張。已開發國家人均醫療費用支出的增加也促進了治療方法的廣泛普及。

3. 新產品上市：各公司積極推出先進治療方法，以滿足未被滿足的醫療需求，進而提高市場滲透率。

抑制因子

新興市場的高成本和有限的普及程度阻礙了富血小板血漿（PRP）療法的推廣。例如，在美國，每次PRP注射的費用約為500至2000美元，而且需要多次注射才能達到預期效果。其他療法，如物理治療和口服藥物，成本更低，這限制了發展中地區的市場成長。

市場區隔

副產品：

  • 預計到 2026 年，透明質酸 (HA) 注射將佔市場佔有率的 66.38%，這主要得益於骨關節炎盛行率的上升和臨床意識的提高。
  • 皮質類固醇注射被廣泛用作一線治療方法。
  • 由於血小板濃縮血漿 (PRP) 注射在疼痛管理方面具有良好的臨床效果，因此預計其複合年成長率 (CAGR) 將最高。

依關節類型：

  • 到 2026 年，由於膝骨關節炎的高發生率，膝關節注射將佔市場主導地位，市場佔有率達到 48.32%。
  • 隨著人們對髖關節、手腕及其他關節相關疾病的認知和診斷水準的提高，預計此類疾病的發生率將穩定上升。

依分銷管道：

  • 到 2026 年，零售藥局將佔 85.31% 的市場佔有率，這主要得益於其便利性和價格優勢。
  • 由於監管支持和價格下降，網路藥局發展勢頭強勁。
  • 隨著前來就診的整形外科疾病患者人數增加，醫院藥局也不斷發展壯大。

區域趨勢

  • 北美：受骨關節炎高發生率和政府支持的影響，預計到 2026 年，市場規模將達到 31.9 億美元。
  • 亞太地區：由於日本、中國和印度人口老化，預計該地區將經歷最快的成長。 2026年市場預測：日本5.3億美元，中國4億美元，印度1億美元。
  • 歐洲：由於政府支持和宣傳活動，預計將實現溫和成長。到2026年，英國市場規模預計將達到3.3億美元，德國將達到4億美元。
  • 拉丁美洲和中東/非洲：由於肌肉骨骼疾病的增加和醫療保健基礎設施的改善，預計名義成長。

主要市場參與者

主要企業包括Bioventus、SEIKAGAKU CORPORATION、Zimmer Biomet、Anika Therapeutics、Sanofi、Pacira BioSciences、Teva Pharmaceutical、Ferring BV和Dr. Reddy's Laboratories。每家公司都專注於研發、新產品上市和策略合作，以擴大市場佔有率。

產業趨勢：

  • 2023 年 12 月：Bioventus 與 Aetna Medicare Advantage 合作，提供其骨關節炎治療藥物 DUROLANE。
  • 2022 年 11 月：Annika Therapeutics 的「Cingal」在 III 期試驗中取得了積極成果。
  • 2022 年 3 月：賽諾菲與 IGM Biosciences 合作開發免疫療法。
  • 2022 年 1 月：SEIKAGAKU 成立 SEIKAGAKU North America CORPORATION，以拓展業務。

目錄

第1章：引言

第2章摘要整理

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第4章：主要考慮因素

  • 骨關節炎流行病學分析：主要國家和地區，2025 年
  • 主要疾病盛行率（依主要國家分類，2025 年）
  • 骨關節炎治療進展概述
  • 新產品發布，主要企業
  • 產業重大發展動態－併購與合作
  • 新冠疫情的影響：關節疼痛治療注射藥物市場

第5章：2021-2034年全球注射劑市場分析、洞察與預測

  • 市場分析、洞察與預測：依產品分類。
    • 皮質類固醇注射
    • 玻尿酸注射
    • 富血小板血漿（PRP）注射
    • 其他
  • 市場分析、洞察與預測：依關節類型分類
    • 膝蓋
    • 髖關節
    • 手腕和手
    • 其他
  • 市場分析、洞察與預測：依分銷管道分類
    • 醫院藥房
    • 零售藥房
    • 網路藥房
  • 市場分析、洞察與預測：依地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章：北美注射式關節疼痛治療市場分析、洞察與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第7章：歐洲注射治療市場分析、洞察與預測（2021-2034年）

  • 國家
    • 英國
    • 德國
    • 義大利
    • 法國
    • 西班牙
    • 斯堪地那維亞
    • 其他歐洲國家

第8章：亞太地區注射式關節疼痛治療市場分析、洞察與預測（2021-2034年）

  • 國家
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 東南亞
    • 其他歐洲國家

第9章：拉丁美洲注射式關節疼痛治療市場分析、洞察與預測（2021-2034年）

  • 國家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第10章：中東和非洲注射式關節疼痛治療市場分析、洞察與預測（2021-2034年）

  • 國家
    • GCC
    • 南非
    • 其他中東和非洲國家

第11章 競爭分析

  • 全球市佔率分析（2025 年）
  • 公司簡介
    • Sanofi
    • Teva Pharmaceutical Industries Ltd.
    • Anika Therapeutics, Inc.
    • Bioventus
    • SEIAGAKU CORPORATION
    • Ferring BV
    • Pacira BioSciences, Inc.
    • Dr. Reddy's Laboratories Ltd.
    • Zimmer Biomet
    • Fidia Farmaceutici SpA
Product Code: FBI100871

Growth Factors of joint pain injections Market

The global joint pain injections market was valued at USD 6.34 billion in 2025 and is projected to grow to USD 6.97 billion in 2026, reaching USD 15.67 billion by 2034, reflecting a CAGR of 10.70% during the forecast period. North America led the market in 2025 with a 45.52% share, driven by a high prevalence of osteoarthritis, advanced healthcare infrastructure, and favorable reimbursement policies. The U.S. joint pain injection market is projected to reach USD 5.49 billion by 2032, fueled by rising sports injuries and increasing awareness of joint disorders.

Joint pain injections are widely used for managing pain and inflammation in patients with musculoskeletal disorders, including osteoarthritis, rheumatoid arthritis, and psoriatic arthritis. Corticosteroid injections are the first line of treatment, delivered directly to affected joints. The growing prevalence of musculoskeletal conditions and the focus of key players on developing novel therapies are key drivers of market growth.

During the COVID-19 pandemic, market growth declined due to reduced patient visits. However, post-pandemic recovery has been observed, supported by increasing awareness of musculoskeletal conditions and continuous introduction of innovative products.

Market Trends

The market is witnessing a shift toward minimally invasive procedures such as platelet-rich plasma (PRP) injections, hyaluronic acid (HA) injections, and plasma matrix therapy. These procedures provide rapid drug absorption, prolonged pain relief, and less discomfort, resulting in growing patient preference.

For instance, in August 2021, Bioventus invested in Trice Medical, Inc. to expand minimally invasive technologies for orthopedic procedures. Ongoing research, such as the phase 3 clinical trials conducted by Emory University (2022) using Mesenchymal Stem Cells (MSC) and Bone Marrow Concentrate (BMAC) for knee osteoarthritis, underscores the increasing adoption of innovative treatments.

Market Growth Factors

1. Rising Sports Injuries: Increasing ligament and muscle injuries are driving demand for joint pain injections. In 2022, the National Safety Council (U.S.) reported over 445,000 exercise equipment-related injuries, highlighting the growing patient pool for pain management therapies.

2. Awareness of Musculoskeletal Disorders: Government initiatives and awareness campaigns promote intra-articular injections, supporting market expansion. Higher per capita healthcare expenditure in developed countries also contributes to increased adoption.

3. Novel Product Launches: Companies are actively introducing advanced therapies to address unmet medical needs, enhancing market penetration.

Restraining Factors

High costs and limited access in emerging countries restrict adoption. For example, PRP injections in the U.S. cost around USD 500-2,000 per injection, requiring multiple doses for efficacy. Alternative treatments, such as physical therapy or oral medications, offer lower-cost solutions, limiting market growth in developing regions.

Market Segmentation

By Product:

  • Hyaluronic Acid (HA) injections led with 66.38% share in 2026, driven by growing osteoarthritis prevalence and clinical awareness.
  • Corticosteroid injections are widely used as the first line of treatment.
  • Platelet-Rich Plasma (PRP) injections are expected to show the highest CAGR due to positive clinical outcomes in pain management.

By Joint Type:

  • Knee injections dominated with 48.32% share in 2026, reflecting the high prevalence of knee osteoarthritis.
  • Hip, hand & wrist, and others are projected to grow steadily as awareness and diagnosis increase.

By Distribution Channel:

  • Retail pharmacies accounted for 85.31% share in 2026, driven by accessibility and affordability.
  • Online pharmacies are gaining traction due to regulatory support and lower pricing.
  • Hospital pharmacies continue to grow as hospital visits for orthopedic conditions increase.

Regional Insights

  • North America: Market size USD 3.19 billion in 2026, driven by high osteoarthritis prevalence and government support.
  • Asia Pacific: Fastest growth expected due to aging populations in Japan, China, and India. Market projections for 2026: Japan USD 0.53 billion, China USD 0.4 billion, India USD 0.1 billion.
  • Europe: Moderate growth with government support and awareness initiatives. UK USD 0.33 billion, Germany USD 0.4 billion in 2026.
  • Latin America & Middle East/Africa: Nominal growth due to rising musculoskeletal conditions and improving healthcare infrastructure.

Key Market Players

Major players include Bioventus, SEIKAGAKU CORPORATION, Zimmer Biomet, Anika Therapeutics, Sanofi, Pacira BioSciences, Teva Pharmaceutical, Ferring B.V., and Dr. Reddy's Laboratories. Companies focus on R&D, new product launches, and strategic partnerships to increase market share.

Industry Developments:

  • Dec 2023: Bioventus partnered with Aetna Medicare Advantage to provide access to DUROLANE for knee osteoarthritis.
  • Nov 2022: Anika Therapeutics' Cingal achieved positive Phase III results.
  • March 2022: Sanofi collaborated with IGM Biosciences on immunology therapeutics.
  • Jan 2022: SEIKAGAKU established SEIKAGAKU NORTH AMERICA CORPORATION for expansion.

Conclusion

The joint pain injections market is set to grow from USD 6.34 billion in 2025 to USD 15.67 billion by 2034, at a 10.70% CAGR, driven by increasing musculoskeletal disorders, sports injuries, awareness of minimally invasive procedures, and innovative product launches. North America remains the largest market, while Asia Pacific shows the fastest growth due to demographic shifts. Despite challenges like high costs and limited access in emerging markets, continuous technological innovation and expanding distribution channels are poised to propel market growth throughout the forecast period.

Segmentation By Product

  • Corticosteroid Injections
  • Hyaluronic Acid Injections
  • Platelet Rich Plasma Injections
  • Others

By Joint Type

  • Knee
  • Hip
  • Hand & Wrist
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Geography

  • North America (By Product, Joint Type, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Product, Joint Type, Distribution Channel, and Country/Sub-Region)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Product, Joint Type, Distribution Channel, and Country/Sub-Region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of the Asia Pacific
  • Latin America (By Product, Joint Type, Distribution Channel, and Country/Sub-Region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Product, Joint Type, Distribution Channel, and Country/Sub-Region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Epidemiology Analysis of Osteoarthritis, Key Countries/ Region, 2025
  • 4.2. Prevalence of Key Disorders, by Key Countries, 2025
  • 4.3. Overview of Advancements in Therapies for Treatment of Osteoarthritis
  • 4.4. New Product Launches, Key Players
  • 4.5. Key Industry Developments - Mergers, Acquisitions, and Partnerships
  • 4.6. Impact of COVID-19 on Joint Pain Injections Market

5. Global Joint Pain Injections Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Product
    • 5.1.1. Corticosteroid Injections
    • 5.1.2. Hyaluronic Acid Injections
    • 5.1.3. Platelet Rich Plasma Injections
    • 5.1.4. Others
  • 5.2. Market Analysis, Insights and Forecast - By Joint Type
    • 5.2.1. Knee
    • 5.2.2. Hip
    • 5.2.3. Hand & Wrist
    • 5.2.4. Others
  • 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.3.1. Hospital Pharmacies
    • 5.3.2. Retail Pharmacies
    • 5.3.3. Online Pharmacies
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Joint Pain Injections Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Product
    • 6.1.1. Corticosteroid Injections
    • 6.1.2. Hyaluronic Acid Injections
    • 6.1.3. Platelet Rich Plasma Injections
    • 6.1.4. Others
  • 6.2. Market Analysis, Insights and Forecast - By Joint Type
    • 6.2.1. Knee
    • 6.2.2. Hip
    • 6.2.3. Hand & Wrist
    • 6.2.4. Others
  • 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.3.1. Hospital Pharmacies
    • 6.3.2. Retail Pharmacies
    • 6.3.3. Online Pharmacies
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Joint Pain Injections Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Product
    • 7.1.1. Corticosteroid Injections
    • 7.1.2. Hyaluronic Acid Injections
    • 7.1.3. Platelet Rich Plasma Injections
    • 7.1.4. Others
  • 7.2. Market Analysis, Insights and Forecast - By Joint Type
    • 7.2.1. Knee
    • 7.2.2. Hip
    • 7.2.3. Hand & Wrist
    • 7.2.4. Others
  • 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.3.1. Hospital Pharmacies
    • 7.3.2. Retail Pharmacies
    • 7.3.3. Online Pharmacies
  • 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.4.1. U.K.
    • 7.4.2. Germany
    • 7.4.3. Italy
    • 7.4.4. France
    • 7.4.5. Spain
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of the Europe

8. Asia Pacific Joint Pain Injections Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Product
    • 8.1.1. Corticosteroid Injections
    • 8.1.2. Hyaluronic Acid Injections
    • 8.1.3. Platelet Rich Plasma Injections
    • 8.1.4. Others
  • 8.2. Market Analysis, Insights and Forecast - By Joint Type
    • 8.2.1. Knee
    • 8.2.2. Hip
    • 8.2.3. Hand & Wrist
    • 8.2.4. Others
  • 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Retail Pharmacies
    • 8.3.3. Online Pharmacies
  • 8.4. Market Analysis, Insights and Forecast - By Country/Sub-Region
    • 8.4.1. Japan
    • 8.4.2. China
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Southeast Asia
    • 8.4.6. Rest of the Europe

9. Latin America Joint Pain Injections Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Product
    • 9.1.1. Corticosteroid Injections
    • 9.1.2. Hyaluronic Acid Injections
    • 9.1.3. Platelet Rich Plasma Injections
    • 9.1.4. Others
  • 9.2. Market Analysis, Insights and Forecast - By Joint Type
    • 9.2.1. Knee
    • 9.2.2. Hip
    • 9.2.3. Hand & Wrist
    • 9.2.4. Others
  • 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.3.1. Hospital Pharmacies
    • 9.3.2. Retail Pharmacies
    • 9.3.3. Online Pharmacies
  • 9.4. Market Analysis, Insights and Forecast - By Country/Sub-Region
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Rest of Latin America

10. Middle East and Africa Joint Pain Injections Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Product
    • 10.1.1. Corticosteroid Injections
    • 10.1.2. Hyaluronic Acid Injections
    • 10.1.3. Platelet Rich Plasma Injections
    • 10.1.4. Others
  • 10.2. Market Analysis, Insights and Forecast - By Joint Type
    • 10.2.1. Knee
    • 10.2.2. Hip
    • 10.2.3. Hand & Wrist
    • 10.2.4. Others
  • 10.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.3.1. Hospital Pharmacies
    • 10.3.2. Retail Pharmacies
    • 10.3.3. Online Pharmacies
  • 10.4. Market Analysis, Insights and Forecast - By Country/Sub-Region
    • 10.4.1. GCC
    • 10.4.2. South Africa
    • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Sanofi
      • 11.2.1.1. Overview
      • 11.2.1.2. Products & Services
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Teva Pharmaceutical Industries Ltd.
      • 11.2.2.1. Overview
      • 11.2.2.2. Products & Services
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Anika Therapeutics, Inc.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products & Services
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Bioventus
      • 11.2.4.1. Overview
      • 11.2.4.2. Products & Services
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. SEIAGAKU CORPORATION
      • 11.2.5.1. Overview
      • 11.2.5.2. Products & Services
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Ferring B.V.
      • 11.2.6.1. Overview
      • 11.2.6.2. Products & Services
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Pacira BioSciences, Inc.
      • 11.2.7.1. Overview
      • 11.2.7.2. Products & Services
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Dr. Reddy's Laboratories Ltd.
      • 11.2.8.1. Overview
      • 11.2.8.2. Products & Services
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. Zimmer Biomet
      • 11.2.9.1. Overview
      • 11.2.9.2. Products & Services
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)
    • 11.2.10. Fidia Farmaceutici S.p.A.
      • 11.2.10.1. Overview
      • 11.2.10.2. Products & Services
      • 11.2.10.3. SWOT Analysis
      • 11.2.10.4. Recent Developments
      • 11.2.10.5. Strategies
      • 11.2.10.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Joint Pain Injections Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 2: Global Joint Pain Injections Market Revenue (USD billion) Forecast, by Joint Type, 2021-2034
  • Table 3: Global Joint Pain Injections Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 4: Global Joint Pain Injections Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 5: North America Joint Pain Injections Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 6: North America Joint Pain Injections Market Revenue (USD billion) Forecast, by Joint Type, 2021-2034
  • Table 7: North America Joint Pain Injections Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 8: North America Joint Pain Injections Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 9: Europe Joint Pain Injections Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 10: Europe Joint Pain Injections Market Revenue (USD billion) Forecast, by Joint Type, 2021-2034
  • Table 11: Europe Joint Pain Injections Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 12: Europe Joint Pain Injections Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 13: Asia Pacific Joint Pain Injections Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 14: Asia Pacific Joint Pain Injections Market Revenue (USD billion) Forecast, by Joint Type, 2021-2034
  • Table 15: Asia Pacific Joint Pain Injections Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 16: Asia Pacific Joint Pain Injections Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 17: Latin America Joint Pain Injections Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 18: Latin America Joint Pain Injections Market Revenue (USD billion) Forecast, by Joint Type, 2021-2034
  • Table 19: Latin America Joint Pain Injections Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 20: Latin America Joint Pain Injections Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Middle East & Africa Joint Pain Injections Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 22: Middle East & Africa Joint Pain Injections Market Revenue (USD billion) Forecast, by Joint Type, 2021-2034
  • Table 23: Middle East & Africa Joint Pain Injections Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 24: Middle East & Africa Joint Pain Injections Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Joint Pain Injections Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Joint Pain Injections Market Value Share (%), by Product, 2025 & 2034
  • Figure 3: Global Joint Pain Injections Market Value Share (%), by Joint Type, 2025 & 2034
  • Figure 4: Global Joint Pain Injections Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 5: Global Joint Pain Injections Market Value (USD billion), by Region, 2025 & 2034
  • Figure 6: North America Joint Pain Injections Market Value (USD billion), by Product, 2025 & 2034
  • Figure 7: North America Joint Pain Injections Market Value Share (%), by Product, 2025
  • Figure 8: North America Joint Pain Injections Market Value (USD billion), by Joint Type, 2025 & 2034
  • Figure 9: North America Joint Pain Injections Market Value Share (%), by Joint Type, 2025
  • Figure 10: North America Joint Pain Injections Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 11: North America Joint Pain Injections Market Value Share (%), by Distribution Channel, 2025
  • Figure 12: North America Joint Pain Injections Market Value (USD billion), By Country, 2025 & 2034
  • Figure 13: North America Joint Pain Injections Market Value Share (%), By Country, 2025
  • Figure 14: Europe Joint Pain Injections Market Value (USD billion), by Product, 2025 & 2034
  • Figure 15: Europe Joint Pain Injections Market Value Share (%), by Product, 2025
  • Figure 16: Europe Joint Pain Injections Market Value (USD billion), by Joint Type, 2025 & 2034
  • Figure 17: Europe Joint Pain Injections Market Value Share (%), by Joint Type, 2025
  • Figure 18: Europe Joint Pain Injections Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 19: Europe Joint Pain Injections Market Value Share (%), by Distribution Channel, 2025
  • Figure 20: Europe Joint Pain Injections Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 21: Europe Joint Pain Injections Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 22: Asia Pacific Joint Pain Injections Market Value (USD billion), by Product, 2025 & 2034
  • Figure 23: Asia Pacific Joint Pain Injections Market Value Share (%), by Product, 2025
  • Figure 24: Asia Pacific Joint Pain Injections Market Value (USD billion), by Joint Type, 2025 & 2034
  • Figure 25: Asia Pacific Joint Pain Injections Market Value Share (%), by Joint Type, 2025
  • Figure 26: Asia Pacific Joint Pain Injections Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 27: Asia Pacific Joint Pain Injections Market Value Share (%), by Distribution Channel, 2025
  • Figure 28: Asia Pacific Joint Pain Injections Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 29: Asia Pacific Joint Pain Injections Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 30: Latin America Joint Pain Injections Market Value (USD billion), by Product, 2025 & 2034
  • Figure 31: Latin America Joint Pain Injections Market Value Share (%), by Product, 2025
  • Figure 32: Latin America Joint Pain Injections Market Value (USD billion), by Joint Type, 2025 & 2034
  • Figure 33: Latin America Joint Pain Injections Market Value Share (%), by Joint Type, 2025
  • Figure 34: Latin America Joint Pain Injections Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 35: Latin America Joint Pain Injections Market Value Share (%), by Distribution Channel, 2025
  • Figure 36: Latin America Joint Pain Injections Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 37: Latin America Joint Pain Injections Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 38: Middle East & Africa Joint Pain Injections Market Value (USD billion), by Product, 2025 & 2034
  • Figure 39: Middle East & Africa Joint Pain Injections Market Value Share (%), by Product, 2025
  • Figure 40: Middle East & Africa Joint Pain Injections Market Value (USD billion), by Joint Type, 2025 & 2034
  • Figure 41: Middle East & Africa Joint Pain Injections Market Value Share (%), by Joint Type, 2025
  • Figure 42: Middle East & Africa Joint Pain Injections Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 43: Middle East & Africa Joint Pain Injections Market Value Share (%), by Distribution Channel, 2025
  • Figure 44: Middle East & Africa Joint Pain Injections Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 45: Middle East & Africa Joint Pain Injections Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 46: Global Joint Pain Injections Market Share (%), By Company, 2025